Amylyx Pharmaceuticals withdraws ALS drug Relyvrio/Albrioza from market in US and Canada due to late-stage clinical trial failure.
Amylyx Pharmaceuticals has announced it will withdraw its ALS drug, branded Relyvrio in the US and Albrioza in Canada, from the market in both countries after it failed in a late-stage clinical trial. The drug, approved in 2022, will no longer be available for new patients. Amylyx will also reduce its workforce by 70%.
April 04, 2024
37 Articles